ARTICLE | Clinical News
Fibrillex: Began Phase II/III study
January 22, 2001 8:00 AM UTC
Neurochem Inc. (TSE:NRM), Saint-Laurent, Quebec Product: Fibrillex Business: Metabolic, Renal Therapeutic category: Matrix remodeling Target: Amyloid fiber Description: Oral small molecule inhibitor ...